Press Release : Novartis provides update on Phase -2-

Novartis around the world. Find out more at https://www.novartis.com. 
 
   Novartis is on Twitter. Sign up to follow @Novartis at 
https://twitter.com/novartisnews 
 
   For Novartis multimedia content, please visit 
https://www.novartis.com/news/media-library 
 
   For questions about the site or required registration, please contact 
[e-mail] 
 
   References (to be updated to reflect order in final release). 
 
 
   1. Novartis Data on File 
 
   2. ClinicalTrials.gov. Study of Efficacy and Safety of Pembrolizumab Plus 
      Platinum-based Doublet Chemotherapy With or Without Canakinumab in 
      Previously Untreated Locally Advanced or Metastatic Non-squamous and 
      Squamous NSCLC Subjects (CANOPY-1). Available at: 
      https://clinicaltrials.gov/ct2/show/NCT03631199. Accessed on February 9, 
      2021. 
 
   3. ClinicalTrials.gov. Brief Title: Study of Efficacy and Safety of 
      Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC 
      v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung 
      Cancer Acronym: CANOPY-A (Canopy-A). Available at: 
      https://www.clinicaltrials.gov/ct2/show/NCT03447769. Accessed on February 
      9, 2021. 
 
   4. ClinicalTrials.gov. Phase III Study Evaluating Efficacy and Safety of 
      Canakinumab in Combination With Docetaxel in Adult Subjects With 
      Non-small Cell Lung Cancers as a Second or Third Line Therapy (CANOPY-2). 
      Available at: https://clinicaltrials.gov/ct2/show/NCT03626545. Accessed 
      on February 9, 2021. 
 
   5. ClinicalTrials.gov. A Randomized, Open-label, Phase II Study of 
      Canakinumab or Pembrolizumab as Monotherapy or in Combination as 
      Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung 
      Cancer (CANOPY-N). Available at: 
      https://clinicaltrials.gov/ct2/show/NCT03968419. Accessed on February 9, 
      2021. 
 
   6. Dhimolea E, mAbs 2010;2:3--13; 3. Ilaris [Prescribing Information 
      T2016-102]. 
 
   7. Rondeau JM, Ramage P, Zurini M, Gram H. The molecular mode of action and 
      species specificity of canakinumab, a human monoclonal antibody 
      neutralizing IL-1. MAbs. 2015;7(6):1151-1160. 
 
   8. Novartis data on file: Clinical Trial Protocol CACZ885M2301. 
 
   9. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1 inhibition 
      and the prevention of recurrent cardiovascular events: rationale and 
      design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
      (CANTOS). Am Heart J. 2011;162:597--605. 
 
  10. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. 
      Mol Cancer Res. 2006;4(4):221-233. 
 
  11. World Health Organization. Cancer. Available at: 
      https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed on 
      February 9, 2021. 
 
  12. Lemjabbar-Alaoui H, Hassan O, Yang UW, et al. Lung cancer: biology and 
      treatment options. Biochim Biophys Acta. 2015. 1856(2):189-210. 
 
  13. American Cancer Society. About Lung Cancer. Available at 
      https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. 
      Accessed February 9, 2021. 
 
  14. Siegel R, Miller K, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 
      2020;70(1):7-30. 
 
  15. Rami-Porta R, Asamura H, Traves W, et al. Lung cancer -- major changes in 
      the American Joint Committee on Cancer eight edition cancer staging 
      manual. CA Cancer J Clin. 2017;67:138. 
 
  16. Mascaux C, Tomasini P, Greillier L, et al. Personalised medicine for 
      non-small cell lung cancer. Eur Respir Rev. 2017;26:170066. 
 
  17. National Comprehensive Cancer Network Guidelines. Non-small cell lung 
      cancer. Version 3. 2020. 
 
  18. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with 
      bevacizumab for non-small cell lung cancer. New Engl J Med. 2006; 355: 
      2452-2550. 
 
  19. Gadgeel S, Rodriguez-Abreu D, Speranza G, et al. Updated analysis from 
      KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for 
      previously untreated metastatic nonsquamous non-small cell lung cancer. J 
      Clin Oncol. 2020; 38:1505-1517. 
 
 
   # # # 
 
   Novartis Media Relations 
 
   E-mail: [e-mail] 
 
 
 
 
Anja von Treskow                        Mary Curtin Creaser 
Director, Strategy & Financial          Director, Global Oncology 
Communications                          Communications, 
[phone] (mobile)                Solid Tumors 
[e-mail]           [phone] (mobile) 
                                        [e-mail] 
 
Julie Masow 
Novartis US External Communications 
[phone] 
[e-mail] 
 
   Novartis Investor Relations 
 
   Central investor relations line: [phone] 
 
   E-mail: [e-mail] 
 
 
 
 
Central                                 North America 
Samir Shah             [phone]  Sloan Simpson  [phone] 
Thomas Hungerbuehler   [phone] 
Isabella Zinck         [phone] 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 09, 2021 01:00 ET (06:00 GMT)